AstraZeneca’s Camizestrant Clears India’s SEC Review The Story: AstraZeneca’s camizestrant has received a positive SEC recommendation in India for HR-positive, HER2-negative advanced breast cancer wit...
Key Highlights: Implications: AstraZeneca’s positive SEC recommendation could accelerate Etcamah’s entry into India’s emerging ESR1-mutated breast cancer segment without a local Phase III ...
Key Highlights: Implications: Cipla’s licensing deal adds a potential new HER2-targeted cancer treatment to its pipeline in India, South Africa and five other emerging markets, stren...
Key Highlights: Implications: The approval broadens AstraZeneca’s trastuzumab deruxtecan franchise in India from later-line metastatic use into the earlier, potentially larger HER2-positiv...
